CI Stock Analysis — Cigna
Sector: Healthcare
AI Verdict
Cigna trades at a steep discount to the sector at 8.9x forward earnings with high growth expected, so the numbers look cheap for the growth you're getting if their scale-driven moat holds up.
Competitive Moat
Cigna operates a vertically integrated health insurance and pharmacy benefits platform, giving it scale to negotiate lower costs and cross-sell services to large employers. Its moat comes from entrenched relationships with corporate clients and regulatory complexity that makes switching providers difficult.
Summary
Cigna's forward P/E of 8.9x with nearly 37% expected earnings growth makes it a standout on value screens in healthcare.
Where It Stands
The stock is down -8.13% over the past year, trades at just 8.9x next year's earnings versus a healthcare sector median of 22x, and its RSI of 43.4 signals cooling momentum after recent declines.
Key Metrics
- RSI: 43.4 — Neutral
- Trailing P/E: 12.2x
- Forward P/E: 8.9x
- PEG Ratio: 0.33
- Earnings Growth: +0.4%
- Revenue Growth: +0.1%
- Market Cap: $75.8B
- Dividend Yield: 0.02%
- 1-Year Return: -8.13%
- 52-Week High: $323.10
- 52-Week Low: $239.51
Analyst Consensus
28 Buy · 5 Hold · 0 Sell (33 analysts)
Bull Case
With analysts forecasting 36.9% EPS growth and a forward P/E of 8.9x, you're paying a low price for rapid earnings expansion if Cigna's integrated model delivers.
Bear Case
If the P/E reverts even partway to the sector median (from 8.9x to 15x), a further derating could erase any EPS gains if growth disappoints or regulatory risk rises.
Catalyst to Watch
Watch for quarterly earnings and any regulatory updates on pharmacy benefit management, as upside or downside surprises could quickly re-rate the stock.